Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing,...

IonQ may be better positioned than QBTS after the 2026 sell-off, as a clearer revenue outlook, backlog growth, and platform strategy support its...

Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising competition...

Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.

Norwegian Cruise is reshaping revenue management as pricing, marketing and deployment gaps weigh on its 2026 outlook.

DelveInsight’s “PARP inhibitor Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline...

Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity...

AVAV expands its tactical UAS portfolio and upgrades drive demand, positioning the company to tap rising defense needs and boost long-term revenue...

DUK gains 11.7% in 3 months as nuclear strength and aggressive renewable expansion plans boost its clean energy outlook and long-term growth...

DUK gains 11.7% in 3 months as nuclear strength and aggressive renewable expansion plans boost its clean energy outlook and long-term growth...